These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 430729)

  • 21. Plasma and cryoprecipitate manufactured from whole blood held overnight at room temperature meet quality standards.
    Serrano K; Scammell K; Weiss S; Culibrk B; Levin E; Gyöngyössy-Issa M; Devine DV
    Transfusion; 2010 Feb; 50(2):344-53. PubMed ID: 19843287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is the continued use of UK plasma sourced cryoprecipitate justified? Response to Makris.
    Idris SF; Hadjinicolaou AV; Sweeney M; Winthrop C; Balendran G; Besser M
    Br J Haematol; 2015 Mar; 168(6):910-1. PubMed ID: 25270161
    [No Abstract]   [Full Text] [Related]  

  • 23. Is the continued use of UK plasma sourced cryoprecipitate justified?
    Makris M
    Br J Haematol; 2015 Mar; 168(6):908-10. PubMed ID: 25302409
    [No Abstract]   [Full Text] [Related]  

  • 24. Cryoprecipitate: no longer the best therapeutic choice in congenital fibrinogen disorders?
    Bevan DH
    Thromb Res; 2009 Dec; 124 Suppl 2():S12-6. PubMed ID: 20109651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Whether fibrinogen concentrates are necessary in Russia?].
    Galstian GM; Berkovskiĭ AL; Zhuravlev VV; Polokhov DM; Savchenko VG
    Anesteziol Reanimatol; 2014; (3):49-59. PubMed ID: 25306685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A protocol for the preparation of cryoprecipitate and cryodepleted plasma.
    Sparrow RL; Greening DW; Simpson RJ
    Methods Mol Biol; 2011; 728():259-65. PubMed ID: 21468954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cryoprecipitate and the plastic blood-bag system: provision of adequate replacement therapy for routine treatment of haemophilia.
    Bennett E; Dormandy KM; Churchill WG; Coward AR; Smith M; Cleghorn TE
    Br Med J; 1967 Apr; 2(5544):88-91. PubMed ID: 6020855
    [No Abstract]   [Full Text] [Related]  

  • 28. Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems.
    Burnouf T; Caron C; Radosevich M; Goubran HA; Goudemand J; El-Ekiaby M
    Haemophilia; 2008 Sep; 14(5):956-62. PubMed ID: 18565126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determinants of factor VIII recovery in cryoprecipitate.
    Kasper CK; Myhre BA; McDonald JD; Nakasako Y; Feinstein DI
    Transfusion; 1975; 15(4):312-22. PubMed ID: 1166504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Occurrence of serum hepatitis following the administration of Cohn's fraction I or fibrinogen and antihemophilic globulin (AHG) respectively].
    Fábryová L; Hrubisko M
    Vnitr Lek; 1970 Feb; 16(2):123-6. PubMed ID: 5309309
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of cryoprecipitate with fibrinogen concentrate for acquired hypofibrinogenaemia.
    Theodoulou A; Berryman J; Nathwani A; Scully M
    Transfus Apher Sci; 2012 Apr; 46(2):159-62. PubMed ID: 22227402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cryoprecipitate: an outmoded treatment?
    Yang L; Stanworth S; Baglin T
    Transfus Med; 2012 Oct; 22(5):315-20. PubMed ID: 22994448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simple method for preparation of cryoprecipitate (CP) and cryodepleted plasma (CDP).
    Prohaska W; Kretschmer V
    Infusionsther Klin Ernahr; 1984 Dec; 11(6):342-4. PubMed ID: 6441780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of fibrinogen content in cryoprecipitate by temperature manipulation during plasma processing.
    Farrugia A; Grasso S; Douglas S; Harrap R; Oates A; Young I; James J; Whyte G
    Transfusion; 1992 Oct; 32(8):755-9. PubMed ID: 1412684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Freeze dried cryoprecipitate: a clinical evaluation.
    Hambley H; Davidson JF; Walker ID; Small M; Prentice CR
    J Clin Pathol; 1983 May; 36(5):574-6. PubMed ID: 6404949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemophilia treatment. Predicting the long-term risk of HIV exposure by cryoprecipitate.
    Evatt B; Austin H; Leon G; Ruiz-Sáez A; de Bosch N
    Haemophilia; 2000 Jul; 6 Suppl 1():128-32. PubMed ID: 10982279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma exchange donation of cryoprecipitate after DDAVP stimulation: an alternative source of factor VIII.
    McLeod BC; Scott JP
    Prog Clin Biol Res; 1990; 324():189-98. PubMed ID: 2106687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Protocol for the Preparation of Cryoprecipitate and Cryo-depleted Plasma for Proteomic Studies.
    Sparrow RL; Simpson RJ; Greening DW
    Methods Mol Biol; 2017; 1619():23-30. PubMed ID: 28674874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cryoprecipitate concentrates of factor 8 for surgery in hemophiliacs.
    Cooke JV; Holland PV; Shulman NR
    Ann Intern Med; 1968 Jan; 68(1):39-47. PubMed ID: 5635330
    [No Abstract]   [Full Text] [Related]  

  • 40. A high-potency, single-donor cryoprecipitate of known factor VIII content dispensed in vials.
    McLeod BC; Sassetti RJ; Cole ER; Scott JP
    Ann Intern Med; 1987 Jan; 106(1):35-40. PubMed ID: 3098152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.